CLASSIC HODGKIN LYMPHOMA
Clinical trials for CLASSIC HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new CLASSIC HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for CLASSIC HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for seniors with hodgkin lymphoma: Chemo-Free combo shows promise
Disease control OngoingThis study tests a combination of two drugs, nivolumab and brentuximab vedotin, in people aged 60 or older (or younger people who cannot handle standard chemo) with untreated Hodgkin lymphoma. The goal is to see if this drug pair can shrink or eliminate the cancer without the har…
Matched conditions: CLASSIC HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Academic and Community Cancer Research United • Aim: Disease control
Last updated May 17, 2026 09:19 UTC
-
New combo therapy aims to beat High-Risk hodgkin lymphoma in kids
Disease control OngoingThis study tests whether adding the targeted drug brentuximab vedotin to standard chemotherapy works better than chemo alone for children and young adults with high-risk Hodgkin lymphoma. About 600 participants with stage IIB (with bulk), IIIB, IVA, or IVB disease will be randoml…
Matched conditions: CLASSIC HODGKIN LYMPHOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
Smart scan guides lymphoma therapy, spares unneeded drugs
Disease control OngoingThis study tests a personalized approach for people with early-stage Hodgkin lymphoma (stages I-II). Doctors use PET scans to see how well the cancer responds to initial chemotherapy, then adjust the treatment plan—adding or skipping certain drugs—to improve outcomes and reduce s…
Matched conditions: CLASSIC HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Academic and Community Cancer Research United • Aim: Disease control
Last updated May 07, 2026 18:43 UTC
-
Immunotherapy combo shows promise in advanced hodgkin lymphoma trial
Disease control OngoingThis study compares two immunotherapy drugs (nivolumab or brentuximab vedotin) given with standard chemotherapy for people aged 12 and older with newly diagnosed stage III or IV classical Hodgkin lymphoma. The goal is to see which combination better shrinks cancer or delays its r…
Matched conditions: CLASSIC HODGKIN LYMPHOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 07, 2026 18:39 UTC